Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation

Yoshihiko Ichikawa, Mohsen Ghanefar, Marina Bayeva, Rongxue Wu, Arineh Khechaduri, Sathyamangla V. Naga Prasad, R Kannan Mutharasan, Tejaswitha Jairaj Naik, Hossein Ardehali*

*Corresponding author for this work

Research output: Contribution to journalArticle

265 Citations (Scopus)

Abstract

Doxorubicin is an effective anticancer drug with known cardiotoxic side effects. It has been hypothesized that doxorubicin-dependent cardiotoxicity occurs through ROS production and possibly cellular iron accumulation. Here, we found that cardiotoxicity develops through the preferential accumulation of iron inside the mitochondria following doxorubicin treatment. In isolated cardiomyocytes, doxorubicin became concentrated in the mitochondria and increased both mitochondrial iron and cellular ROS levels. Overexpression of ABCB8, a mitochondrial protein that facilitates iron export, in vitro and in the hearts of transgenic mice decreased mitochondrial iron and cellular ROS and protected against doxorubicin-induced cardiomyopathy. Dexrazoxane, a drug that attenuates doxorubicin-induced cardiotoxicity, decreased mitochondrial iron levels and reversed doxorubicin-induced cardiac damage. Finally, hearts from patients with doxorubicin-induced cardiomyopathy had markedly higher mitochondrial iron levels than hearts from patients with other types of cardiomyopathies or normal cardiac function. These results suggest that the cardiotoxic effects of doxorubicin develop from mitochondrial iron accumulation and that reducing mitochondrial iron levels protects against doxorubicin-induced cardiomyopathy.

Original languageEnglish (US)
Pages (from-to)617-630
Number of pages14
JournalJournal of Clinical Investigation
Volume124
Issue number2
DOIs
StatePublished - Feb 3 2014

Fingerprint

Doxorubicin
Iron
Cardiomyopathies
Mitochondria
Dexrazoxane
Cardiotoxicity
Mitochondrial Proteins
Cardiac Myocytes
Pharmaceutical Preparations
Transgenic Mice

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ichikawa, Y., Ghanefar, M., Bayeva, M., Wu, R., Khechaduri, A., Naga Prasad, S. V., ... Ardehali, H. (2014). Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. Journal of Clinical Investigation, 124(2), 617-630. https://doi.org/10.1172/JCI72931
Ichikawa, Yoshihiko ; Ghanefar, Mohsen ; Bayeva, Marina ; Wu, Rongxue ; Khechaduri, Arineh ; Naga Prasad, Sathyamangla V. ; Mutharasan, R Kannan ; Jairaj Naik, Tejaswitha ; Ardehali, Hossein. / Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 2. pp. 617-630.
@article{9d5eb367cb9b4105a1455c931dc2c498,
title = "Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation",
abstract = "Doxorubicin is an effective anticancer drug with known cardiotoxic side effects. It has been hypothesized that doxorubicin-dependent cardiotoxicity occurs through ROS production and possibly cellular iron accumulation. Here, we found that cardiotoxicity develops through the preferential accumulation of iron inside the mitochondria following doxorubicin treatment. In isolated cardiomyocytes, doxorubicin became concentrated in the mitochondria and increased both mitochondrial iron and cellular ROS levels. Overexpression of ABCB8, a mitochondrial protein that facilitates iron export, in vitro and in the hearts of transgenic mice decreased mitochondrial iron and cellular ROS and protected against doxorubicin-induced cardiomyopathy. Dexrazoxane, a drug that attenuates doxorubicin-induced cardiotoxicity, decreased mitochondrial iron levels and reversed doxorubicin-induced cardiac damage. Finally, hearts from patients with doxorubicin-induced cardiomyopathy had markedly higher mitochondrial iron levels than hearts from patients with other types of cardiomyopathies or normal cardiac function. These results suggest that the cardiotoxic effects of doxorubicin develop from mitochondrial iron accumulation and that reducing mitochondrial iron levels protects against doxorubicin-induced cardiomyopathy.",
author = "Yoshihiko Ichikawa and Mohsen Ghanefar and Marina Bayeva and Rongxue Wu and Arineh Khechaduri and {Naga Prasad}, {Sathyamangla V.} and Mutharasan, {R Kannan} and {Jairaj Naik}, Tejaswitha and Hossein Ardehali",
year = "2014",
month = "2",
day = "3",
doi = "10.1172/JCI72931",
language = "English (US)",
volume = "124",
pages = "617--630",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "2",

}

Ichikawa, Y, Ghanefar, M, Bayeva, M, Wu, R, Khechaduri, A, Naga Prasad, SV, Mutharasan, RK, Jairaj Naik, T & Ardehali, H 2014, 'Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation', Journal of Clinical Investigation, vol. 124, no. 2, pp. 617-630. https://doi.org/10.1172/JCI72931

Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. / Ichikawa, Yoshihiko; Ghanefar, Mohsen; Bayeva, Marina; Wu, Rongxue; Khechaduri, Arineh; Naga Prasad, Sathyamangla V.; Mutharasan, R Kannan; Jairaj Naik, Tejaswitha; Ardehali, Hossein.

In: Journal of Clinical Investigation, Vol. 124, No. 2, 03.02.2014, p. 617-630.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation

AU - Ichikawa, Yoshihiko

AU - Ghanefar, Mohsen

AU - Bayeva, Marina

AU - Wu, Rongxue

AU - Khechaduri, Arineh

AU - Naga Prasad, Sathyamangla V.

AU - Mutharasan, R Kannan

AU - Jairaj Naik, Tejaswitha

AU - Ardehali, Hossein

PY - 2014/2/3

Y1 - 2014/2/3

N2 - Doxorubicin is an effective anticancer drug with known cardiotoxic side effects. It has been hypothesized that doxorubicin-dependent cardiotoxicity occurs through ROS production and possibly cellular iron accumulation. Here, we found that cardiotoxicity develops through the preferential accumulation of iron inside the mitochondria following doxorubicin treatment. In isolated cardiomyocytes, doxorubicin became concentrated in the mitochondria and increased both mitochondrial iron and cellular ROS levels. Overexpression of ABCB8, a mitochondrial protein that facilitates iron export, in vitro and in the hearts of transgenic mice decreased mitochondrial iron and cellular ROS and protected against doxorubicin-induced cardiomyopathy. Dexrazoxane, a drug that attenuates doxorubicin-induced cardiotoxicity, decreased mitochondrial iron levels and reversed doxorubicin-induced cardiac damage. Finally, hearts from patients with doxorubicin-induced cardiomyopathy had markedly higher mitochondrial iron levels than hearts from patients with other types of cardiomyopathies or normal cardiac function. These results suggest that the cardiotoxic effects of doxorubicin develop from mitochondrial iron accumulation and that reducing mitochondrial iron levels protects against doxorubicin-induced cardiomyopathy.

AB - Doxorubicin is an effective anticancer drug with known cardiotoxic side effects. It has been hypothesized that doxorubicin-dependent cardiotoxicity occurs through ROS production and possibly cellular iron accumulation. Here, we found that cardiotoxicity develops through the preferential accumulation of iron inside the mitochondria following doxorubicin treatment. In isolated cardiomyocytes, doxorubicin became concentrated in the mitochondria and increased both mitochondrial iron and cellular ROS levels. Overexpression of ABCB8, a mitochondrial protein that facilitates iron export, in vitro and in the hearts of transgenic mice decreased mitochondrial iron and cellular ROS and protected against doxorubicin-induced cardiomyopathy. Dexrazoxane, a drug that attenuates doxorubicin-induced cardiotoxicity, decreased mitochondrial iron levels and reversed doxorubicin-induced cardiac damage. Finally, hearts from patients with doxorubicin-induced cardiomyopathy had markedly higher mitochondrial iron levels than hearts from patients with other types of cardiomyopathies or normal cardiac function. These results suggest that the cardiotoxic effects of doxorubicin develop from mitochondrial iron accumulation and that reducing mitochondrial iron levels protects against doxorubicin-induced cardiomyopathy.

UR - http://www.scopus.com/inward/record.url?scp=84893845965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893845965&partnerID=8YFLogxK

U2 - 10.1172/JCI72931

DO - 10.1172/JCI72931

M3 - Article

VL - 124

SP - 617

EP - 630

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 2

ER -

Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. Journal of Clinical Investigation. 2014 Feb 3;124(2):617-630. https://doi.org/10.1172/JCI72931